Clinical Research Directory
Browse clinical research sites, groups, and studies.
Skin Transcriptional Profiles In Psoriatic Patients Under Adalimumab Biotherapy
Sponsor: Poitiers University Hospital
Summary
The expertise in the characterization of transcriptomics profile in lesional psoriatic skin and on the availability of innovative therapy for these patients.The investigators propose to follow the modification of the skin transcriptomics profile in psoriatic patients during successful Adalimumab biotherapy. Skin transcriptomics profiles of normal skin, psoriatic non lesional skin, and psoriatic lesional skin before and after biotherapy will be compared. The investigators will focus on the modification of the cytokine "signature" in these skin lesions and of some markers of keratinocyte inflammation. The modification of the transcriptomics profile induced by the biotherapy will be correlated to the clinical response Psoriasis Area and Severity Index.
Official title: Characterization of Skin Th17 Transcriptional Profiles in Psoriatic Patients Under Adalimumab Biotherapy
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
18
Start Date
2013-01
Completion Date
2013-09
Last Updated
2026-06-24
Healthy Volunteers
No
Conditions
Interventions
Adalimumab Every Week
Adalimumab was administered subcutaneously at a dose of 80 mg at Week 0 and 40 mg every other week starting from Week 1 to Week 16.
Locations (1)
Chu Poitiers
Poitiers, France